Roche

News

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

News

Roche's Gazyva breaks new ground in lupus

Already approved for kidney damage in lupus, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

News

ESMO: Clear air emerges between Roche SERD and its rivals

Has Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

News

FDA clears Roche, Lilly Alzheimer's blood test

A blood test developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer's more quickly has been approved by the FDA.

News

Roche gets EU nod for kidney disease algorithm

Roche and Klinrisk have picked up a CE-mark for an AI tool that can be used to predict renal function decline in patients with chronic kidney disease.

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's Gazyva breaks new ground in lupus

Chugai buys 'Asia lag' firm Renalys for $98m upfront

ESMO: Clear air emerges between Roche SERD and its rivals

FDA clears Roche, Lilly Alzheimer's blood test

Roche gets EU nod for kidney disease algorithm

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks